Clinical trialNCT06918990RecruitingPhase 1Interventional

Treatment of Antibody-Mediated Rejection (ABMR) With CarBel

SponsorNational Institute of Allergy and Infectious Diseases (NIAID)Enrollment25Kidney Transplant Rejection

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to evaluate the safety of carfilzomib and belatacept, administered with steroids and maintenance immunosuppression, in kidney transplant recipients with donor-specific antibody (DSA)-associated graft injury. Participants will be followed for 52 weeks after starting investigational therapy, including protocol biopsies at 3 months and 12 months after start of investigational therapy. The study will also assess changes in immune cell responses, blood and urine biomarkers, and biopsy-based pathomic features associated with antibody-mediated graft injury.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Scott Sanoff, MD, Ph.D.
Duke University Medical Center: Transplantation
Study Chair
clinicaltrials.gov ↗
Stuart J Knechtle, M.D.
Duke University Medical Center: Transplantation
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

11 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

University of Alabama Medical Center (site # 71136)
Birmingham, Alabama, United States
Not, yet, recruiting
Mayo Clinic Arizona (site # 71144)
Phoenix, Arizona, United States
Recruiting
Ucla Medical Center (site #: 71123)
Los Angeles, California, United States
Not, yet, recruiting
Northwestern University, Feinberg School of Medicine (site # 71110)
Chicago, Illinois, United States
Recruiting
Washington University (site # 71157)
St Louis, Missouri, United States
Recruiting
Nyu Langone Health (site # 71177)
New York, New York, United States
Recruiting
Duke University (site # 71139)
Durham, North Carolina, United States
Recruiting
Christ Hospital (site # 71195)
Cincinnati, Ohio, United States
Not, yet, recruiting
University of Cincinnati (site # 71118)
Cincinnati, Ohio, United States
Recruiting
Cleveland Clinic (site # 71101)
Cleveland, Ohio, United States
Recruiting
University of Wisconsin Madison (site # 71112)
Madison, Wisconsin, United States
Not, yet, recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Belatacept →Carfilzomib →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 27 May 2026
Primary completion: 30 Jun 2027
Completion: 30 Jun 2027
Last update posted: 10 Aug 2026
Registered enrollment: 25
Registry id: NCT06918990

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.